Detailed price information for Catheter Precision Inc (VTAK-A) from The Globe and Mail including charting and trades.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation ...
Catheter Precision plans to divest its cardiac AP business, including LockeT and VIVO devices, to focus on aviation after ...
Extra belly fat may be a bigger red flag for heart health than body mass index (BMI), according to a new study. BMI, a screening tool widely used to determine whether people are at a "normal" weight, ...
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...
Results from the multi-center CRT-NEXT study demonstrated that CRT-DX is as safe and effective as conventional three-lead CRT ...
Pulse Biosciences (Nasdaq:PLSE) announced today that it enrolled the first patients in its NANOPULSE-AF study.
Here’s what they found, plus some key limitations.
Pulse Biosciences (PLSE) highlights promising AFib catheter data and IDE-cleared pivotal trial progress—plus thyroid ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
Pulse Biosciences is keeping the noise level up by announcing the enrollment of the first patients in the NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently ...
Real-world evidence to be presented at the American College of Cardiology Scientific Session 2026 highlights impact of Viz HCM, developed as part of a multi-year agreement with Bristol Myers Squibb, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results